Madrigal Pharmaceuticals Announces Q3 Sales Growth and Updates Clinical Trial Timelines
Madrigal Pharmaceuticals (MDGL) reported strong commercial momentum for its product Rezdiffra, noting rapid growth in the MASH market. During the Q3 2026 management update, CEO William Sibold highlighted that the business is performing exceptionally well as demand accelerates. The company provided key updates on its clinical pipeline, anticipating a readout for the MAESTRO-NASH study in late 2027. Additionally, Madrigal is planning an expansive MAESTRO-CSPH study involving over 2,000 patients to further expand its market presence.
Tickers: $MDGL
Topics: earnings market expansion pharmaceuticals revenue growth
Read the full article at Seeking Alpha
Part of the story Rhythm Pharmaceuticals Announces Q3 Revenue Growth and Phase III Trial Timeline for Bivamelagon (2 articles)